Executive Summary
Protherics PLC is an integrated biopharmaceutical company focused on the development and marketing of products for critical care and oncology. With headquarters in London, the Company has approximately 190 employees across its operations in the UK, US and Australia. The Company's lead programmes are VoraxazeTM, for the control of high dose methotrexate therapy in cancer, where discussions are on-going with the US and EU regulators regarding marketing approvals, and CytoFabTM, for severe sepsis, which has been out-licensed to AstraZeneca and is being prepared for a pivotal phase 3 trial. Protherics' strategy is to use the revenues generated from its marketed products to help fund the advancement of its development pipeline. The majority of the Company's revenues are derived from two critical care products, CroFabTM (pit viper antivenom) and DigiFabTM (digoxin antidote) which were developed in-house and are sold in the US through Fougera Inc, a division of Altana AG. Additional products in the development pipeline include Prolarix TM (selective prodrug based chemotherapy), currently in phase 1; and an Angiotensin Vaccine (treatment of hypertension), where encouraging phase 2a results have led to an improved formulation entering pre-clinical testing.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
